Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.47 |
| ▸ | TXNRD1 | Q16881 | 3/20 | 0.43 |
| ▸ | MERTK | Q12866 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25289487 | 0.81 | MERTK (0.44) | TXNRD1MERTKMAPTALDH1A1HTT | |
| SCHEMBL539558 | 0.80 | BRD4 (0.50) | BRD4TXNRD1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL7018840 | 0.78 | MERTK (0.42) | TXNRD1MERTKKMT2AMAPTALDH1A1 | |
| SCHEMBL9984233 | 0.76 | BRD4 (0.62) | BRD4SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL5553628 | 0.75 | SYK (0.43) | TXNRD1MERTKLMNAKMT2AMAPT | |
| SCHEMBL19172520 | 0.75 | LMNA (0.51) | MERTKLMNAMEN1KMT2AMAPT | |
| SCHEMBL10740434 | 0.74 | TXNRD1 (0.58) | TXNRD1MAPTHTT | |
| SCHEMBL15514986 | 0.74 | MERTK (0.49) | TXNRD1MERTKSMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL29983153 | 0.74 | MERTK (0.49) | TXNRD1MERTKSMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL25637888 | 0.74 | SMN1; SMN2 (0.40) | BRD4TXNRD1SMN1; SMN2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | BRD4 934/4885TXNRD1 2453/4885MERTK 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.